Ethyl loflazepate is not approved for marketing in the United States by the U.S. Food and Drug Administration. Available data indicate that the infant dose from milk might be rather high. An alternate drug with more published data and lower milk levels is preferred, especially while nursing a newborn or preterm infant. If ethyl loflazepate is used, monitor the infant for sedation, poor feeding and poor weight gain.